Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apnimed's board compensation committee granted non-qualified stock options to purchase an aggregate of 428,428 shares to 10 new non-executive employees on August 31, 2026, at an exercise price of $26.85 per share. The awards were made under the company's 2026 Inducement Plan as employment inducements under Nasdaq Listing Rule 5635(c)(4), with one-fourth vesting on each employee's first anniversary and the remainder in monthly installments over three years.
Key figures
- Exercise price
- 26.85
- Pdufa goal date
- February 28, 2027
- Vesting schedule
- 25% on first anniversary of start date, then equal monthly installments over three years
- Option grant shares
- 428428
- New employees granted
- 10
- Phase 3 trials completed
- 2
- Inducement plan adoption date
- August 21, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.